Health Trials

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

ConditionsHealthy Volunteer StudyHepatic ImpairmentRenal Impairment
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-80
SponsorAtea Pharmaceuticals, Inc.

About this trial

To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose

Eligibility criteria

Qualifiers

Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug

Females must have a negative pregnancy test at Screening and prior to dosing

BMI of 18.5 to 43.0 kg/m2

Willing to comply with the study requirements and to provide written informed consent

Disqualifiers

Pregnant or breastfeeding

Infected with hepatitis B virus, hepatitis C virus or HIV

Abuse of alcohol or drugs

Use of other investigational drugs within 28 days of dosing

Trial design

Treatments tested in this trial

  • Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination

Treatment groups

28 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Atea Pharmaceuticals, Inc.

Lead sponsor

Source ClinicalTrials.gov